Does methylene blue have meaningful evidence for Alzheimer’s disease, and how do experimental derivatives differ from ordinary methylene blue?

There is a real clinical research program involving methylthioninium-related compounds that target tau aggregation, but its findings need careful interpretation. A 2026 phase 3 report studied hydromethylthionine mesylate, or HMTM, in 598 people with amyloid-confirmed mild cognitive impairment or dementia due to Alzheimer’s disease. It did not demonstrate a significant treatment difference on its two primary clinical endpoints at 52 weeks. The authors attributed this partly to activity in the low-dose methylthioninium control group and reported favorable biomarker findings and later cognitive separation in the mild cognitive impairment subgroup.[1]

Those later findings justify further evaluation, but they do not turn a missed primary comparison into an uncomplicated proof of benefit. HMTM is a particular chemical formulation delivered under a trial protocol; ordinary methylene blue drops cannot be assumed to have equivalent exposure, efficacy or safety. Nor do biomarker changes alone establish preserved independence or prevention of dementia in healthy users. This research should not be used to replace an Alzheimer’s assessment or prescribed treatment with an online product, especially given methylene blue’s important medication interactions.[1][2]